Across TCGA pan-cancer cohorts, KIAA1841 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KIAA1841 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher KIAA1841 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIAA1841 expression acts as an unfavorable survival marker.
SKCM, BLCA, and UCEC are the cancer types where KIAA1841 Mutation most reproducibly stratifies survival.